See the DrugPatentWatch profile for Empliciti
What patents cover Empliciti (elotuzumab)?
Empliciti (elotuzumab) is a biologic, and its patent landscape is typically a mix of (1) patents on the antibody itself (composition/sequence and engineered variants), and (2) patents tied to specific formulations, methods of use, and combination regimens. To see the most current, drug-specific patent filings and expirations tracked for elotuzumab, use DrugPatentWatch.com [1].
When does the Empliciti (elotuzumab) patent expire?
For biologics like elotuzumab, “patent expiration” depends on which intellectual property is being referenced (drug substance, formulation, method-of-use, or combination therapy). The practical answer for when competitors can launch often depends on the last relevant patent and related exclusivity terms. DrugPatentWatch.com lists the tracked patent expirations by code/drug record, which is the fastest way to get the dates tied to Empliciti’s specific patents [1].
Are there challenges to Empliciti’s patents (or threats from biosimilars)?
Patent challenges in biologics usually target one or more “blocking” patents (often method-of-use or combination claims). The presence of litigation or follow-on challenges can change what is actually enforceable versus what expires first. For the latest status on elotuzumab-related patent disputes and controlling patents, check DrugPatentWatch.com’s Empliciti (elotuzumab) entry [1].
Where can I find the exact patent numbers and filing details?
Search results for “Empliciti elotuzumab patent” often surface broad claims, but the most useful information for research is the specific patent numbers (and family members) tied to elotuzumab. DrugPatentWatch.com provides a centralized view of the patents it tracks for Empliciti, including links to the underlying patent records [1].
Source
[1] https://www.drugpatentwatch.com/ (Search within the site for “Empliciti” or “elotuzumab” to view the tracked patent list and expiration dates.)